By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
持续经营业务-骨科医疗器械业务234.76M21.24%
持续经营业务-心律管理业务229.7M20.78%
持续经营业务-大动脉及外周血管介入业务187.86M16.99%
持续经营业务-心血管介入业务181.75M16.44%
已终止经营业务-神经介入业务110.47M9.99%
Continuing business-other95.61M8.65%
持续经营业务-结构性心脏病业务42.72M3.86%
持续经营业务-手术机器人业务22.52M2.04%
View all
By Product
Currency:USD
2025/FY
Stock NameRevenueRatio
持续经营业务-骨科医疗器械业务234.76M21.24%
持续经营业务-心律管理业务229.7M20.78%
持续经营业务-大动脉及外周血管介入业务187.86M16.99%
持续经营业务-心血管介入业务181.75M16.44%
已终止经营业务-神经介入业务110.47M9.99%
Continuing business-other95.61M8.65%
持续经营业务-结构性心脏病业务42.72M3.86%
持续经营业务-手术机器人业务22.52M2.04%
View all
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
持续经营业务-中国(经营所在国)421.47M38.13%
Continuing Business-Europe325.95M29.49%
持续经营业务-亚洲(除中国外)108.93M9.85%
已终止经营业务-中国(经营所在国)97.48M8.82%
Continuing Business-North America79.58M7.20%
Continuing Business-South America42.33M3.83%
Continuing business-other16.66M1.51%
Other5.38M0.49%
已终止经营业务-南美洲4.4M0.40%
已终止经营业务-亚洲(除中国外)3.22M0.29%
View all
